Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RITA B CHUANG

Allopathic & Osteopathic Physicians Family Medicine

NPI
1497854962
CMS profile
339716
Location
HENDERSON, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$1,433.13

89 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,419.24 88
Education $13.89 1

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 89 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RITA B CHUANG

NPI 1497854962 · CMS profile ID 339716

Allopathic & Osteopathic Physicians / Family Medicine

HENDERSON, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 89 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1497854962?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RITA B CHUANG, NPI 1497854962, CMS profile ID 339716. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 89 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1497854962?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). RITA B CHUANG, NPI 1497854962, CMS profile ID 339716. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 89 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1497854962?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
RITA B CHUANG, NPI 1497854962, CMS profile ID 339716, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 89 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1497854962?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

89 matching records · $1,433.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 89 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 89.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biohaven Pharmaceuticals, Inc. $22.3612/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748974837 CMS
Otsuka America Pharmaceutical, Inc. $17.6412/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748701489 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.6712/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737506869 CMS
Amgen Inc. $23.7312/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741281791 CMS
Amgen Inc. $13.8912/07/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741461145 CMS
World Class Technology Corporation $12.6212/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749824999 CMS
AstraZeneca Pharmaceuticals LP $16.7112/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735846811 CMS
Allergan, Inc. $13.0212/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723811597 CMS
PFIZER INC. $15.4411/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743802757 CMS
Esperion Therapeutics, Inc. $16.3111/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737188211 CMS
Allergan, Inc. $7.3311/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723811593 CMS
Allergan, Inc. $15.4411/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723811589 CMS
AstraZeneca Pharmaceuticals LP $14.2811/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736080079 CMS
Lilly USA, LLC $14.7611/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728625059 CMS
Gilead Sciences, Inc. $24.8010/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747960671 CMS
GlaxoSmithKline, LLC. $11.9910/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738889503 CMS
Allergan, Inc. $9.9410/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723811585 CMS
Otsuka America Pharmaceutical, Inc. $16.1910/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748701483 CMS
AbbVie Inc. $14.8110/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721731281 CMS
PFIZER INC. $14.4210/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743791157 CMS
AstraZeneca Pharmaceuticals LP $17.5910/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736229193 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.6710/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737506867 CMS
AstraZeneca Pharmaceuticals LP $13.5810/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736289123 CMS
PFIZER INC. $10.5910/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743791155 CMS
Allergan, Inc. $13.4209/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723811581 CMS
Otsuka America Pharmaceutical, Inc. $19.3409/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748701477 CMS
Merck Sharp & Dohme Corporation $20.0009/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747757765 CMS
Amarin Pharma Inc. $15.1709/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740087499 CMS
PFIZER INC. $15.5009/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743776627 CMS
PFIZER INC. $11.9009/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743779805 CMS
Lilly USA, LLC $13.1209/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728628537 CMS
Novo Nordisk Inc $13.9509/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744883093 CMS
Amgen Inc. $26.1409/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741281793 CMS
AstraZeneca Pharmaceuticals LP $12.2309/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735873889 CMS
IRONWOOD PHARMACEUTICALS, INC $14.9509/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749793431 CMS
Janssen Pharmaceuticals, Inc $14.8609/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719379205 CMS
PFIZER INC. $11.4608/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743761737 CMS
Allergan, Inc. $9.7608/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723811577 CMS
Allergan, Inc. $14.9408/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723811573 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.2608/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737506865 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.7408/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720506477 CMS
AstraZeneca Pharmaceuticals LP $14.7308/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735976361 CMS
Novo Nordisk Inc $16.0708/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744804525 CMS
PFIZER INC. $11.0008/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743436341 CMS
Allergan, Inc. $17.5308/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723811569 CMS
Eisai Inc. $16.7307/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751260119 CMS
PFIZER INC. $12.2507/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743747513 CMS
AstraZeneca Pharmaceuticals LP $16.2107/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736107245 CMS
Novo Nordisk Inc $13.0607/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745029417 CMS
PFIZER INC. $16.3407/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743747585 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,839.57 139
PY2020 $1,433.13 89
PY2021 $1,935.28 96
PY2022 $1,401.79 64
PY2023 $3,265.71 67
PY2024 $1,619.65 16
PY2025 $876.10 8

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $109,405.49 16
PY2021 Principal investigator $79,823.05 120
PY2020 Principal investigator $98,717.42 98
PY2019 Recipient $901.66 10
PY2019 Principal investigator $172,883.69 87

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

98 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $900.00 12/31/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721315817
Principal investigator 1 Allergan, Inc. $919.80 12/31/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with moderately to Severely Active Croh No dispute reported 06/30/2026 721316175
Principal investigator 1 Allergan, Inc. $860.94 12/31/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 721316203
Principal investigator 1 Novo Nordisk AS $2,198.88 12/22/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431565
Principal investigator 1 Novo Nordisk AS $72.00 12/18/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 822171015
Principal investigator 1 Novo Nordisk AS $400.00 12/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431563
Principal investigator 1 Novo Nordisk AS $10,788.12 11/30/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431561
Principal investigator 1 Allergan, Inc. $169.00 11/24/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721309695
Principal investigator 1 Novo Nordisk AS $945.00 10/29/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431559
Principal investigator 1 Allergan, Inc. $86.00 10/01/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721301131
Principal investigator 1 Novo Nordisk AS $3,303.72 09/24/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431555
Principal investigator 1 Novo Nordisk AS $200.00 09/24/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431557
Principal investigator 1 Allergan, Inc. $315.00 09/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721299601
Principal investigator 1 Allergan, Inc. $955.00 08/27/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721293641
Principal investigator 1 Novo Nordisk AS $9,026.64 08/27/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431551
Principal investigator 1 Novo Nordisk AS $400.00 08/27/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431553
Principal investigator 1 Allergan, Inc. $385.00 08/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721292065
Principal investigator 1 Allergan, Inc. $420.00 08/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721292367
Principal investigator 1 Allergan, Inc. $700.00 08/11/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721289447
Principal investigator 1 Allergan, Inc. $315.00 08/04/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721288387
Principal investigator 1 Allergan, Inc. $86.00 08/04/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721288415
Principal investigator 1 Allergan, Inc. $184.00 08/01/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721288171
Principal investigator 1 Allergan, Inc. $250.00 08/01/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721288177
Principal investigator 1 Allergan, Inc. $250.00 08/01/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721288179
Principal investigator 1 Novo Nordisk AS $2,810.16 07/30/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431549
Principal investigator 1 Allergan, Inc. $9,172.25 07/15/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721284309
Principal investigator 1 Novo Nordisk AS $3,603.96 06/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431545
Principal investigator 1 Novo Nordisk AS $1,728.00 06/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431547
Principal investigator 1 Eli Lilly and Company $1,003.13 06/01/2020 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE No dispute reported 06/30/2026 728743777
Principal investigator 1 Novo Nordisk AS $6,761.88 05/28/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431447
Principal investigator 1 Novo Nordisk AS $400.00 05/28/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431449
Principal investigator 1 Allergan, Inc. $385.00 05/26/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721277101
Principal investigator 1 Allergan, Inc. $50.00 05/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721273903
Principal investigator 1 Allergan, Inc. $50.00 05/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721273905
Principal investigator 1 Allergan, Inc. $191.00 05/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721273953
Principal investigator 1 Allergan, Inc. $800.00 05/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721273959
Principal investigator 1 Novo Nordisk AS $5,042.52 04/30/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431445
Principal investigator 1 Allergan, Inc. $385.00 04/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721272447
Principal investigator 1 Allergan, Inc. $1,600.00 04/16/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721270733
Principal investigator 1 Novo Nordisk AS $6,565.32 03/24/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431441
Principal investigator 1 Novo Nordisk AS $200.00 03/24/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431443
Principal investigator 1 Novo Nordisk AS $24.99 03/19/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431541
Principal investigator 1 Allergan, Inc. $700.00 03/05/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721262193
Principal investigator 1 Allergan, Inc. $8,036.00 03/03/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721261807
Principal investigator 1 Novo Nordisk AS $7,920.72 02/27/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431437
Principal investigator 1 Novo Nordisk AS $200.00 02/27/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431439
Principal investigator 1 Allergan, Inc. $50.00 02/24/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721259099
Principal investigator 1 Allergan, Inc. $50.00 02/24/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721259101
Principal investigator 1 Allergan, Inc. $191.00 02/24/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721259261
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431451
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431453
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431455
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431457
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431459
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431461
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431463
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431465
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431467
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431469
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431471
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431473
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431475
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431477
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431479
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431481
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431483
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431485
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431487
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431489
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431491
Principal investigator 1 Novo Nordisk AS $12.75 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431493
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431495
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431497
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431499
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431501
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431503
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431505
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431507
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431509
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431511
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431513
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431515
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431517
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431519
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431521
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431523
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431525
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431527
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431529
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431531
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431533
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431535
Principal investigator 1 Novo Nordisk AS $28.45 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431537
Principal investigator 1 Novo Nordisk AS $16.25 02/10/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431539
Principal investigator 1 Allergan, Inc. $115.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721250785
Principal investigator 1 Novo Nordisk AS $5,362.74 01/28/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431435
Principal investigator 1 Novo Nordisk AS $75.00 01/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US, INC.
EX9536-4388 No dispute reported 06/30/2026 742431543
Principal investigator 1 Allergan, Inc. $191.00 01/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH N01 MIDCO N01 LTD
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721245645